Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 7/20 | 0.83 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.78 |
| ▸ | F10 | P00742 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | PLAT | P00750 | 1/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL1145308 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4374 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1145427 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4308143 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL6852675 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3175687 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1817517 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29572887 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL23356536 | 0.99 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3145300 | 0.99 | F2 (0.82) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169874-A1 | ANTICOAGULANT REVERSAL AGENTS | CIRAPARANTAG HOLDINGS GMBH (CH) | 2021-06-10 | — | — | US | disclosed |
| US-20210048443-A1 | METHOD FOR DIAGNOSING HAEMOSTASIS DISORDERS USING ACTIVATED CHARCOAL | UNIVERSITÉ DE NAMUR ASBL (BE) | 2021-02-18 | — | — | US | disclosed |
| US-20180207152-A1 | ANTICOAGULANT REVERSAL AGENTS | CIRAPARANTAG HOLDINGS GMBH (CH) | 2018-07-26 | — | — | US | disclosed |
| US-9877961-B2 | Anticoagulant reversal agents | PEROSPHERE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20170056396-A1 | ANTICOAGULANT REVERSAL AGENTS | PINWHEEL THERAPEUTICS INC. | 2017-03-02 | — | — | US | disclosed |
| US-9522892-B2 | Anticoagulant reversal agents | PEROSPHERE INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2785700-B1 | ANTICOAGULANT REVERSAL AGENTS | PEROSPHERE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2785700-A1 | ANTICOAGULANT REVERSAL AGENTS | Perosphere, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014033551-A2 | THE USE OF DIRECT THROMBIN INHIBITORS IN CRITICALLY ILL PATIENTS | MEDIZINISCHE UNIVERSITAET INNSBRUCK (AT) | 2014-03-06 | — | — | WO | disclosed |
| US-7589106-B2 | Alcohol free formulation of argatroban | EAGLE PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300272-A1 | Alcohol free formulation of argatroban | EAGLE PHARMACEUTICALS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300272-A1 | Alcohol free formulation of argatroban | EAGLE PHARMACEUTICALS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080076798-A1 | Alcohol free formulation of argatroban | SCIDOSE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076798-A1 | Alcohol free formulation of argatroban | SCIDOSE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080026474-A1 | ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20050208095-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050187140-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| WO-2004026252-A2 | GLIOMA TREATMENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187140-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | F2 447/4885PRSS1 2624/4885F10 403/4885 |
| US-20080300272-A1 | Alcohol free formulation of argatroban | MMAB, ADH1A, AADAT | F2 62/4885PRSS1 1833/4885F10 408/4885 |
| US-20210169874-A1 | ANTICOAGULANT REVERSAL AGENTS | SERPINC1, F2, PROC | F2 2/4885PRSS1 135/4885F10 12/4885 |
| US-20180207152-A1 | ANTICOAGULANT REVERSAL AGENTS | SERPINC1, F2, PROC | F2 2/4885PRSS1 135/4885F10 12/4885 |
| US-20080076798-A1 | Alcohol free formulation of argatroban | MMAB, ADH1A, AADAT | F2 62/4885PRSS1 1833/4885F10 408/4885 |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | PLAT, F2, TFPI | F2 2/4885PRSS1 85/4885F10 49/4885 |
| US-20170056396-A1 | ANTICOAGULANT REVERSAL AGENTS | SERPINC1, F2, PROC | F2 2/4885PRSS1 135/4885F10 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.